Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Development of a novel CD19/BCMA dual CAR-T for autoimmune diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

WDWen DingDMDonghui MaMLMin Luo

Discussion

Loading...

Member takes

Overview

This research demonstrates improved cytotoxicity of CD19/BCMA dual CAR-T in autoimmune diseases, highlighting safety concerns like cytokine release syndrome.

Key Points

  • Develop a novel CD19/BCMA dual CAR-T therapy for treating autoimmune diseases while addressing safety concerns.
  • Developed humanized anti-CD19 and anti-BCMA monoclonal antibodies.
  • Constructed CD19/BCMA dual CAR structures including tandem and compound CARs with varying co-stimulatory domains.
  • Engineered a LNP-mRNA-based platform for transient CAR-T cell engineering.
  • Dual CAR-T therapy showed enhanced cytotoxicity against pathogenic immune cells.
  • Addressing safety concerns mitigated risks of cytokine release syndrome.
  • Successfully developed a novel dual CAR-T construct with innovative engineering platform.

Cite This Study

Ding et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d911https://doi.org/10.1182/blood-2025-7639
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 152: Toward an <i>in vivo</i> anti-BCMA/CD19 CAR-T cell treatment of B cell-mediated autoimmune diseases.2026
  2. 2Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma2024 · 1 citations
  3. 3Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma2025
  4. 4BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations
  5. 5CAR-T cells targeting CD79b and CD19 exhibit robust antitumour activity against B cell lymphoma2025 · 1 citations